Benzinga.com

Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO

On Monday, in its earnings release, Myriad Genetics Inc. (NASDAQ:MYGN) said Unitedhealth Group Inc’s (NYSE:UNH) UnitedHealthcare will stop covering multi-gene panel pharmacogenetic testing, including ...
Seeking Alpha

Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing

SALT LAKE CITY, April 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in genetic testing and precision medicine, revealed results from a multi-year, real-world study ...
Seeking Alpha

Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing

SALT LAKE CITY, April 21, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc (MYGN). (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that the Journal of ...
Enid News & Eagle

Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing

SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated ...